Comparative safety of oral Janus kinase inhibitors versus dupilumab in patients with atopic dermatitis: A population-based cohort study
Top Cited Papers
- 7 August 2024
- journal article
- research article
- Published by Elsevier in Journal of Allergy and Clinical Immunology
- Vol. 154 (5) , 1195-1203.e3
Abstract
No abstract availableKeywords
Funding Information
- National Institutes of Health
- National Institute of Allergy and Infectious Diseases (R01 AI142872, R01 AI172938, R21 AI151591, K24 AI106822)
This publication has 38 references indexed in Scilit:
- Use patterns of systemic immunomodulators in the United States before and after dupilumab approval in adults with atopic dermatitisPharmacoepidemiology and Drug Safety, 2022
- Target Trial EmulationJAMA, 2022
- Association of Risk of Incident Venous Thromboembolism With Atopic Dermatitis and Treatment With Janus Kinase InhibitorsJAMA Dermatology, 2022
- Dupilumab-Associated Adverse Events During Treatment of Allergic DiseasesClinical Reviews in Allergy & Immunology, 2022
- Effect of JAK inhibitors on high- and low-density lipoprotein in patients with rheumatoid arthritis: a systematic review and network meta-analysisClinical Rheumatology, 2022
- Efficacy and Safety of Upadacitinib vs Dupilumab in Adults With Moderate-to-Severe Atopic DermatitisJAMA Dermatology, 2021
- Integrated Safety Analysis of Abrocitinib for the Treatment of Moderate-to-Severe Atopic Dermatitis From the Phase II and Phase III Clinical Trial ProgramAmerican Journal of Clinical Dermatology, 2021
- Using Propensity Score Methods to Create Target Populations in Observational Clinical ResearchJAMA, 2020
- Infections in Dupilumab Clinical Trials in Atopic Dermatitis: A Comprehensive Pooled AnalysisAmerican Journal of Clinical Dermatology, 2019
- The performance of different propensity score methods for estimating marginal hazard ratiosStatistics in Medicine, 2012